Sponsored by Lunit, in collaboration with Volpara Health, this session is poised to pique your intrigue with discussions about the impact of AI on interval cancer rates and personalized screening. Please join us as we continue to Conquer Cancer through AI, together.
Learning Objectives:
Define false-negative and interval cancers
Assess the potential impact of AI on interval cancer rates
Describe imaging and clinicopathological features associated with AI-detected false-negative cancers
.jpg "Manisha Bahl, MD, MPH photo")